Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 8/20 | 0.46 |
| ▸ | ESR1 | P03372 | 7/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26040051 | 1.00 | ESR2 (0.46) | ESR2ESR1APPHSD17B1HSD17B2 | |
| SCHEMBL12562779 | 0.88 | ESR1 (0.48) | ESR2ESR1APPHSD17B1HSD17B2 | |
| SCHEMBL12562811 | 0.86 | HSD17B1 (0.43) | ESR2ESR1APPHSD17B1HSD17B2 | |
| SCHEMBL12562832 | 0.86 | HSD17B1 (0.43) | ESR2ESR1APPHSD17B1HSD17B2 | |
| SCHEMBL10300223 | 0.86 | ESR1 (0.50) | ESR2ESR1APPHSD17B1HSD17B2 | |
| SCHEMBL25165759 | 0.79 | ESR1 (0.34) | ESR2ESR1HSD17B1HSD17B2 | |
| SCHEMBL20804575 | 0.78 | ESR1 (0.61) | ESR2ESR1APPHSD17B1HSD17B2 | |
| SCHEMBL12562738 | 0.78 | ESR1 (0.61) | ESR2ESR1APPHSD17B1HSD17B2 | |
| SCHEMBL12562824 | 0.77 | HSD17B1 (0.60) | ESR2ESR1APPHSD17B1HSD17B2 | |
| SCHEMBL26040038 | 0.76 | ESR1 (0.66) | ESR2ESR1APPCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230262998-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND SOLID-STATE IMAGING DEVICE | Sony Group Corporation (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230262998-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND SOLID-STATE IMAGING DEVICE | Sony Group Corporation (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
| EP-2518075-A1 | INDUCED LAYER MATERIAL FOR PREPARING NON-PLANAR METAL PHTHALOCYANINE WEAK EPITAXY GROWTH THIN FILM | Shanghai Casail Display Technology Ltd. (CN) | 2012-10-31 | — | — | EP | disclosed |
| US-20110152541-A1 | INDUCING LAYER MATERIALS FOR WEAK EPITAXIAL FILMS OF NON-PLANAR METAL PHTHALOCYANINE | SHANGHAI CASAIL DISPLAY TECHNOLOGY LTD. (CN) | 2011-06-23 | — | — | US | disclosed |
| US-20110152541-A1 | INDUCING LAYER MATERIALS FOR WEAK EPITAXIAL FILMS OF NON-PLANAR METAL PHTHALOCYANINE | SHANGHAI CASAIL DISPLAY TECHNOLOGY LTD. (CN) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | PNLIP, PDXK, DGKK | ESR2 2493/4885ESR1 3908/4885APP 2740/4885 |
| US-20110152541-A1 | INDUCING LAYER MATERIALS FOR WEAK EPITAXIAL FILMS OF NON-PLANAR METAL PHTHALOCYANINE | CDYL, PAX3, PAXBP1 | ESR2 574/4885ESR1 717/4885APP 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.